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BACKGROUND: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to
radiotherapy in the control of metastatic tumour growth.
METHODS: The NLCQ-1, RB6145 and tirapazamine were assessed against the spontaneously metastasising KHT model. Subcutaneous
KHT tumours (250mm
3) were irradiated with 25Gy (single fraction) to control primary growth. Equitoxic drug treatments (NLCQ-1
(10mgkg
–1) once daily; RB6145 (75mgkg
–1) and tirapazamine (13mgkg
–1) twice daily) were administered 3–6 days post-
radiotherapy when hypoxic cells were evident in lung micrometastases. Mice were culled when 50% of controls exhibited detrimental
signs of lung metastases.
RESULTS: In total, 95% of control mice presented with lung disease. This was significantly reduced by NLCQ-1 (33%; P¼0.0002) and
RB6145 (60%; P¼0.02). Semi-quantitative grading of lung disease revealed a significant improvement with all treatments, with
NLCQ-1 proving most efficacious (median grades: control, 4; NLCQ, 0 (Po0.0001); RB6145, 1 (Po0.001), tirapazamine,
3( P¼0.007)). Positron emission tomography (PET) was evaluated as a non-invasive means of assessing metastatic development.
Primary and metastatic KHT tumours showed robust uptake of [
18F]fluorodeoxyglucose ([
18F]FDG). Metastatic burden discernable
by [
18F]FDG PET correlated well with macroscopic and histological lung analysis.
CONCLUSION: The hypoxia-selective cytotoxin NLCQ-1 controls metastatic disease and may be a successful adjuvant to radiotherapy
in the clinical setting.
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Hypoxia is a common physiological abnormality in solid tumours
and is known to be associated with resistance to conventional
therapeutics. Further, there is a large body of evidence to suggest
that tumour hypoxia is linked to metastatic progression (Lunt
et al, 2009). These data, together with the low incidence of hypoxia
in physiologically normal tissues, mark tumour hypoxia as an
attractive and exploitable therapeutic target. Compounds known as
bioreductive drugs or hypoxia-selective cytotoxins have been
developed. These are inert pro-drugs that are activated by
reductive enzymes in a hypoxic environment generating toxic
metabolites that cause cell damage and death by various
mechanisms (Stratford and Workman, 1998; McKeown et al,
2007). Ordinarily, hypoxia-selective cytotoxins are used in
combination with other treatment strategies that preferentially
target rapidly proliferating cells and/or whose efficacy is limited in
the absence of oxygen. Synergistic interactions are often observed
in this setting (Stratford et al, 2003).
Given the experimental and clinical links between hypoxia and
metastases, we earlier hypothesised that selective targeting of
hypoxic cells before radiotherapy would reduce the propensity for
metastases. Indeed, we showed that the hypoxic cytotoxin
tirapazamine reduces metastatic dissemination from hypoxic
primary tumours when it is given before radiotherapy (Lunt
et al, 2005). This could suggest that either the hypoxic cells are the
population most likely to metastasise or that hypoxic cell
signalling influences dissemination.
An alternative way in which hypoxia-selective cytotoxins could
be exploited in an anti-metastatic strategy is based on the
assumption that early stage metastases will contain hypoxic cell
foci, as has been recognised for a number of years (Stanley et al,
1977). These could have an important function in the induction of
an ‘angiogenic switch’ as hypoxia is an important physiological
trigger for the increased expression of a number of angiogenic
cytokines and their receptors including vascular endothelial
growth factor (Semenza, 2009).
The aim of this study was to ascertain whether hypoxia-selective
cytotoxins could be given as adjuvants to radiotherapy to control
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smetastases. This has been analysed using the KHT murine sarcoma
established in its syngeneic host (C3H mouse). The KHT model
was used as it develops spontaneous lung metastases after primary
subcutaneous tumours are controlled with radiotherapy (Baker
et al, 1981; Lunt et al, 2005). The model is very aggressive, with
metastases forming in a reproducible temporal and spatial manner
allowing robust evaluation of anti-metastatic strategies. Three
different hypoxia-selective cytotoxins were used: tirapazamine,
RB6145 (less emetic bromoethyl precursor of the bioreductive
RSU1069) and one of the newer generations of bioreductive
compounds, NLCQ-1 (NSC 709257). These drugs differ in terms of
the oxygen concentration required for cytotoxicity. Both RB6145
and NLCQ-1 are nitroimidazoles that require oxygen levels below
0.1% for maximal bioactivation (Koch, 1993; K Williams and
MV Papadopoulou, unpublished data). Tirapazamine becomes
increasingly cytotoxic as oxygen levels decrease (Koch, 1993).
Recent work has suggested that the metabolism of tirapazamine at
intermediate oxygen tensions may compromise the penetration of
the drug into hypoxic regions (Kyle and Minchinton, 1999; Hicks
et al, 2006). Indeed, NLCQ-1 was rationally designed to specifically
possess weak DNA affinity to allow for good extra-vascular
diffusion and penetration to hypoxic tumour tissue. The NLCQ-1
enhances the effect of radiotherapy, radioimmunotherapy and
chemotherapy and compares favourably with tirapazamine when
assessed in head-to-head studies (Papadopoulou and Bloomer,
2003). Here, we show that the nitroimidazoles and in particular
NLCQ-1 significantly inhibit metastatic growth when administered
post-radiotherapy. Further, we have investigated the use of
positron emission tomography (PET) as a clinically relevant
imaging tool to assess metastatic burden. Using this non-invasive
technique, we found that KHT lung metastases are avid by
[
18F]fluorodeoxyglucose ([
18F]FDG) PET and that lung burden
assessed through imaging equated well with alternative assessment
methods. Given that metastases are the most common reason for
mortality in cancer patients, these findings have marked clinical
relevance and support the use of hypoxia-selective chemotherapy
in the adjuvant setting.
MATERIALS AND METHODS
Cell culture
KHT cell cultures were established from viably frozen stock tumour
pieces. These were rapidly thawed to 371C, freeze medium removed
and the tumour piece cross-chopped in a small volume of RPMI
medium supplemented with 10% foetal calf serum and 2mM
glutamine (RPMI complete). The resultant brie was then repeatedly
pippeted to disaggregate remaining cell clumps and the suspension
plated into a standard culture flask. All in vivo experiments were
undertaken using cells established from the same KHT stock
tumour after minimal in vitro passaging (o6 passages).
Proliferation assay
KHT cells were seeded at 500 cells per well into 96-well plates. Cells
were left 2–3h to attach. NLCQ-1 was prepared at a range of
concentrations by serial dilution and added to the cells for 3h. For
anoxic exposure, cell seeding and drug preparation were under-
taken in an anoxic chamber (Bactron anaerobic chamber, Sheldon
Manufacturing, OR, USA) using plastics that had been held within
the anoxic chamber for at least 3 days and medium that had
similarly been primed to the hypoxic condition. The drug-
containing medium was then replaced with fresh culture medium.
Cells were cultured for 4 days under standard conditions (95% air,
5% CO2, humidified). The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5
diphenytetrazolium bromide) was then added to a final concen-
tration of 5mgml
–1 for 4h. Medium was then removed and the
cells lysed in dimethylsulphoxide. The optical density (OD) of the
formazan product was read at 540nm using a 96-well plate reader
(BioTek mQuant, Bedfordshire, UK).
In vivo studies
The tumour studies analysing spontaneous metastases formation
were performed as earlier described in Lunt et al (2005). Briefly,
5 10
5 KHT cells prepared in a 0.1ml volume of serum-free RPMI
were implanted subcutaneously on the back of female C3H mice
(age 10–12 weeks). Tumour volume measurements were initiated
once a palpable tumour formed. Tumour localised radiotherapy
(25Gy) was administered under ambient conditions to non-
anaesthetised mice-bearing tumours of 200–300mm
3 in size that
were restrained in lead shielded containers. Treatment with
bioreductive agents was initiated 72h after radiotherapy in
combination studies. Drugs were all given by intra-peritoneal (IP)
injection in fractionated protocols over a 4-day period. Doses were
as follows: NLCQ-1, 15mgkg
 1; RB6145, 75mgkg
 1; tirapazamine,
13mgkg
 1. The NLCQ-1 was given once daily and RB6145 and
tirapazamine twice daily at 12h intervals. These were equitoxic
dosing regimens for the three compounds. Control mice received
0.9% saline. For metastasis experiments, external evidence of lung
metastases in 50% of control mice (weight loss and/or laboured
breathing) indicated, from experience, that the experimental end
point had been reached. In addition, subsets of tumour-bearing
mice were killed 1, 3 and 5 days post-radiotherapy or 16h after the
completion of the treatment with bioreductive drugs. In all
treatment groups, pimonidazole (60mgkg
 1 IP; Chemicon Inter-
national Inc., CA, USA) was given 2h before killing. Lungs and
residual primary tumours were rapidly excised and either snap
frozen in liquid nitrogen or formalin fixed for histological analysis.
As an alternative method for generating lung ‘metastases’, KHT
cells were administered by tail-vein injection (5 10
4 cells in 0.1ml
per mouse). Fractionated drug treatments commenced 72h after
cell implant. Mouse welfare was monitored at least daily and more
frequently when the experimental end point was approached. All
procedures were carried out in accordance with the Scientific
Procedures Act 1986 and UKCCCR Guidelines 1997 by approved
protocols (Home Office Project Licences 40-1770 and 40-2328 held
by IJS and 40/3212 held by KJW) following institutional guidelines.
Analysis of local control
Primary tumour volumes were monitored post-therapy. Local
control was documented when there was no evidence of primary
tumour at the point of killing. Local treatment failure or evidence
of re-growth described either tumours, which showed little
response to the local therapy (i.e., did not regress) or tumours,
which initially regressed (often to a point where there was no
evidence of tumour), but then re-lapsed and were palpable at
killing.
Scoring of metastatic burden
After treatment, lungs were rapidly excised and fixed in Bouin’s
solution (2.5% in 0.9% saline; Sigma Diagnostics, Gillingham, UK)
to easily visualise tumour deposits. The severity of metastases was
assessed using a semi-quantitative scoring system that has been
described earlier (Lunt et al, 2005). Briefly, the lungs were awarded
a grade from 0 to 5 depending on the extent of disease with a ‘0’
score indicating no visible metastases and ‘5’ indicating 480% of
the lung surface was diseased (Lunt et al, 2005).
Ex vivo clonogenic assay of tumour cell viability
When the potential onset of metastatic disease was apparent in
control mice, mice receiving radiotherapy plus/minus NLCQ-1
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swere culled and lungs were rapidly excised. They were weighed and
an assessment of metastatic burden made according to the criteria
listed above. The lungs were cross-chopped in a small volume of
RPMI complete, supplemented with penicillin and streptomycin
(RPMI P/S). Additional medium was added and the lung brie
passed through a sterile 35mm mesh. The cell suspension was
pelleted, resuspended in phosphate-buffered saline (PBS), pelleted
again and then resuspended in RPMI P/S giving a final preparation
equating to 0.1g lung weight 1ml
 1 medium. This suspension was
serially diluted and each dilution plated in duplicate into six-well
plates. Colony formation was assessed 10 days later.
Positron emission tomography
Tumour studies for PET were carried out as described above. For
the pilot study, animals underwent dynamic [
18F]FDG scanning B9
days after cell implant when xenograft size had reached 200–
250mm
3. Animals were fasted overnight before scanning, staggered
across the group to reflect scanning times. Animals were
anaesthetised with 1–2% isoflurane and injected with B10MBq
[
18F]FDG (Erigal, Keele, UK) intravenously (IV) through the tail
vein. They were then scanned on the quad-high-density avalanche
chamber (HIDAC) system (Oxford Positron Systems, Weston-on-
the-green, UK) with a theoretical resolution of 1mm (Hastings et al,
2007). List mode data were collected for 75min with anaesthesia
being maintained during image acquisition through a nose cone on
the scanning rig, with respiration monitored throughout using
a pressure sensitive pad (Model 1025L, SA Instruments, NJ, USA).
Body temperature was monitored throughout using an infrared
thermometer and maintained by use of a heating pad, a hot air
blower and a heating lamp. Animals were recovered in a warmed
cage. For the main study, animals underwent static [
18F]FDG
scanning at 13 and 20 days post-irradiation. The procedure was
identical to dynamic scanning except that the animals were
anaesthetised for 45min on the bench before being scanned for
a further 15min. Immediately after the last scan, tumours were
excised and fixed in 10% formalin. Pilot [
18F]fluoro-L-thymidine
([
18F]FLT) studies were carried out as described above, with animals
imaged under anaesthesia for 60min after injection with 10MBq
[
18F]FLT. [
18F]FLT was synthesised ‘in house’ using published
protocols (Blocher et al, 2002). Images were reconstructed using
OPL-EM (Reader et al, 2002). Absolute calibration of the images was
achieved by reference to a
22Na source imaged in the field of view in
each scan. This had been validated with a uniformly filled mouse-
sized [
18F] phantom imaged over 2h. Static images were constructed
and uptake values calculated for the region of interest (ROI)
expressed as kBqml
–1. The ROI analysis was undertaken using in-
house developed software. Further normalisation was performed
using the injected dose (from the dose calibrator) and animal weight
to give a standardised uptake value (SUV); SUVmax was calculated
from the maximum voxel value within the ROI and SUVmean as the
average overall voxels. For [
18F]FDG, normalised uptake values
(NUVs) were calculated by dividing SUVmax or SUVmean from the
tumour by that from the brain.
Immunohistochemistry
Lungs In total, 5mm sections were taken from formalin-fixed
paraffin-embedded samples. Pimonidazole adduct formation was
revealed using Hypoxyprobe-1 monoclonal antibody (Chemicon
International Inc.) and the mouse Envision kit (Dako Ltd., Ely,
UK) according to the manufacturer’s guidelines for both reagents.
Sections were counterstained using Gill’s haematoxylin. Haemo-
toxylin and eosin (H&E) staining was undertaken on sequential
sections for comparison.
Primary tumours Cryostat sections (5mm) were prepared from
snap-frozen tumour material and fixed using ice-cold acetone.
Sections were simultaneously treated with rat anti-CD31 (1:250
dilution; Pharmingen, BD Biosciences, Oxford, UK) and Hypoxy-
probe antibody (1:50 dilution in PBS supplemented with
0.1% bovine serum albumin and 0.1% Tween) followed by
TRITC-labelled goat anti-rat (Molecular Probes, Invitrogen Life
Technologies, Paisley, UK) and rabbit anti-mouse FITC (Dako)
antibodies. Vessel density and hypoxic fractions were analysed
using a NIKON Eclipse E800 with associated MetaMorph software.
Vessel density was analysed per unit area of the tumour section
and hypoxia as the fraction positive area as described earlier
(Williams et al, 2007).
Data analysis
Presence or absence of metastases was assessed by Fisher’s exact
test using the online VasserStats package. Local control data was
analysed using Kaplan–Meier plots and log-rank P-values
determined using Origin. Differences in the frequency distribu-
tions of metastatic burden were assessed by Mann–Whitney
U-tests using Origin.
RESULTS
Hypoxic KHT cells are sensitive to NLCQ-1 in vitro, but
NLCQ-1 shows no single agent activity against KHT
tumours in vivo
The hypoxia selectivity of tirapazamine and RSU1069 in the KHT
model has been established earlier (Stratford et al, 1986; Siemann,
1990; Stratford, 1992). Here, initial studies were undertaken to
assess the relative sensitivity of KHT cells to NLCQ-1. Cells were
exposed to NLCQ-1 for 3h under aerobic or anoxic conditions and
proliferation relative to untreated controls assessed 4 days later.
The NLCQ-1 was markedly more toxic against KHT cells exposed
under anoxic vs aerobic conditions (Figure 1A). The NLCQ-1
concentration required to inhibit proliferation by 50% was
202mM±32 (s.e.) in air compared with 2.9mM±1.0 (s.e.) under
anoxic conditions giving a hypoxic selectivity ratio of B70-fold.
To assess whether the cytotoxic effect of NLCQ-1 would translate
into efficacy as a single agent, KHT tumours were established in
C3H mice and treated with fractionated NLCQ-1 treatment
(15mgkg
 1 daily for 4 days). Consistent with our earlier published
observations with the bioreductive agents RB6145 and tirapaza-
mine (Lunt et al, 2005), NLCQ-1 treatment alone has no effect on
the growth of primary KHT tumours (Figure 1B). Earlier
pharmacokinetic studies showed that the peak plasma concentra-
tion of NLCQ-1 after a 10mgkg
–1bolus was 26.8mM at 5min post-
administration (Reid et al, 2003). This suggests that the dose used
in this study would be sufficient to target hypoxic, but not oxic
KHT cells within the tumour mass. The lack of effect of NLCQ-1 as
a single agent suggests that overall tumour growth is dominated by
the oxic population.
Early stage KHT lung micrometastases contain hypoxic
cells
The aim of these studies was to investigate the function of
bioreductive drugs as adjuvants to radiotherapy in the control of
metastatic disease. Initial experiments were undertaken to examine
whether KHT lung micrometastases contained a target hypoxic cell
population. Primary KHT tumours were established and irradiated
with 25Gy. The hypoxic marker pimonidazole was administered
and lungs excised at various times post-radiotherapy. Microme-
tastases were not clearly evident 1-day post-radiotherapy (not
shown). However, by day 3 metastatic deposits that stained
positively for pimonidazole adducts were revealed after immuno-
histochemical analysis (Figure 2A).
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spontaneously arising KHT metastases in the lung
To assess the effects of bioreductive drugs on KHT lung
metastases, treatment was initiated 3 days after radiotherapy of
primary tumours and continued for a 4-day period (see Figure 2B
for a schematic of the treatment schedule). Both primary tumour
growth and the onset of metastases (evidenced by loss of
condition) were monitored in treated and control populations.
Three experiments were undertaken and the data pooled in
Figure 3 (see figure legend for details). In each experiment, there
was no significant difference in the metastatic profile observed in
saline-treated control tumours.
In terms of local control, NLCQ-1 yielded some improvement
over saline (33% vs 18%), but this was not significant (log-rank
P 0.5). However, both tirapazamine and RB6145 were far superior
(Figure 3A) and had a highly significant impact on local control
with 475% of treated mice showing no evidence of primary
tumour re-growth during the course of the experiment (log-rank
Po0.001 for both agents).
In contrast with the effects on primary tumour burden, NLCQ-1
proved most efficacious against metastatic disease. When 50% of
control saline-treated mice showed evidence of metastases, all mice
were killed and lung tumour burden assessed using an earlier
established semi-quantitative scoring index (Lunt et al, 2005).
Eight of 12 NLCQ-1-treated mice had no evidence of macroscopic
disease (Figure 3B). None of the NLCQ-1-treated mice presented
with greater than grade 2 disease and the median metastasis score
was 0. The RB6145 also increased the frequency of lung disease-
free mice compared with controls (40% vs 5%). Here, the median
grade was 1. Somewhat surprisingly, tirapazamine was the least
effective of the agents assessed with a median lung score of 2.5
observed after treatment and only 20% of the mice appear free
from lung tumours. High-grade lung disease was observed in a
significant proportion of treated mice, with 50% of mice
presenting with grade 3 disease or above. Comparing the data
distributions by Mann–Whitney U-test supported the significance
of these qualitative observations (P-values for NLCQ-1, RB6145
and tirapazamine vs saline-treated controls were o0.00001,
o0.001 and 0.007). In the clinical scenario, a single metastatic
lesion can be lethal; therefore, data were also analysed using a
binary score for the presence or absence of metastases. Again the
impact of NLCQ-1 was highly significant (P¼0.0002 vs controls).
The RB6145 also yielded a significant improvement (P¼0.02),
but this was not the case for tirapazamine (P¼0.22; Fisher’s
Exact tests).
To complement the studies into effects against metastases that
spontaneously arise from subcutaneous KHT tumours, experi-
ments were undertaken to assess the impact of NLCQ-1 and
tirapazamine treatment on lung metastases formation after
intravenous injection of KHT tumour cells (experimental metas-
tases). Initial studies were undertaken to determine the injected
cell number required to give metastases over the same time frame
as the interval between radiation and morbidity in the spontaneous
model. In addition, histology was undertaken to ensure that
metastases were present over the course of bioreductive treatment
(days 3–6 post-cell injection inclusive; data not shown). Neither
A
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Figure 2 Hypoxic KHT lung micrometastases are evident 3 days after
radiotherapy of the primary tumours. (A) Primary KHT tumours were
irradiated with 25Gy and lungs excised at various times thereafter.
Pimonidazole was administered before lung excision and adduct formation
(brown staining) revealed after immunohistochemical analysis (top panels).
The H&E staining in comparative sections is shown in the lower panels.
(B) Schematic of treatment protocol.
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Figure 1 NLCQ-1 is an effective hypoxic cytotoxin against KHT cells in
vitro, but does not impair KHT tumour growth in vivo. KHT cells (A) were
exposed to NLCQ-1 under aerobic or anoxic conditions for 3h.
Proliferation was assessed 4 days later by MTT assay. Data points
represent the average relative proliferation compared with untreated
control cells from three experiments (±s.d.). Exposure to anoxia alone did
not influence KHT proliferation (average OD540 aerobic controls 1.4 vs 1.3
for anoxic controls). (B) KHT cells were inoculated into C3H mice. Once
tumours had established NLCQ-1 was administered daily for 4 consecutive
days (15mgkg
–1). Presented are average tumour volume measurements
(±s.e.; n¼8 per group).
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sNLCQ-1 nor tirapazamine caused a significant change in the
distribution of metastastic grade observed compared with saline-
treated controls (P¼0.12 and0.19 for tirapazamine and NLCQ-1,
respectively, n¼6 per group [data not shown]).
NLCQ-1 treatment does not seem to be anti-angiogenic
Recent data have suggested that some bioreductive agents may
have anti-angiogenic effects (Huxham et al, 2006; O’Rourke et al,
2008). An anti-angiogenic effect against the primary tumour could
have conceivably influenced metastatic dissemination post-radio-
therapy in the current studies. To investigate this, vessel density
and hypoxic fraction were assessed in irradiated tumours after
treatment with saline or NLCQ-1. The analysis was undertaken on
tumours excised 16h after the final saline/NLCQ-1 dose (n¼4 per
group). The KHT model is highly vascularised and control
tumours had a vessel density of 86±13 (s.e.) mm
 2.T h eN L C Q - 1
reduced this slightly to 67±17 (s.e.) mm
 2, but the change was
not significant (P¼0.48). Concomitant with the reduction in
vessel density, irradiated NLCQ-1-treated tumours exhibited an
increase in hypoxic fraction compared with saline-treated controls
(13±3 vs 9±1 in controls), but again this did not achieve
significance (P40.05).
Utilisation of non-invasive PET imaging to assess KHT
lung metastases
The experimental end point used in the preceding studies was
defined by a loss of condition in the control group that occurred
3–4 weeks post-radiotherapy. The ability to image metastatic
burden non-invasively using PET was investigated. Preliminary
studies were undertaken using treatment-sized subcutaneous KHT
tumours. Tumour-bearing mice were administered [
18F]FDG or
[
18F]FLT. Primary tumours showed strong uptake of both
[
18F]FDG and [
18F]FLT (Figure 4). Once uptake had been
confirmed in primary tumours, two further studies were under-
taken focused on the use of [
18F]FDG to give an assessment of
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Figure 3 NLCQ-1 yields little improvement in local control compared
with tirapazamine and RB6145, but is superior in the control of metastatic
disease when administered as an adjuvant to radiotherapy. Primary tumour
response was monitored post-treatment with radiotherapy (administered
on day 1) and bioreductive agent or saline (days 4–7) (A). Evidence of
re-growth after treatment (see Materials and Methods for details) was
taken as a loss of local control and this is expressed as per cent of treated
mice with time after treatment. KHT lung metastatic burden was assessed
using a semi-quantitative system when 50% of saline-treated control mice
exhibited evidence of disease (B). The histograms show the frequency
distribution of metastatic grade for each treatment. Data shown were
pooled from three independent experiments. The first compared RB6145
(n¼10) and tirapazamine (n¼10) vs saline control (n¼12); the second
NLCQ-1 (n¼9) vs saline control (n¼7) and the third NLCQ-1 vs saline
control (n¼3/group). There was no significant difference in the control
data for the three experiments. Bioreductive treatments were NLCQ-1,
15mgkg
–1 once daily; tirapazamine 13mgkg
 1 twice daily; RB6145
75mgkg
 1 twice daily or saline twice daily.
A
B
Figure 4 Primary KHT tumours (circled) show robust uptake of both
[
18F]FDG and [
18F]FLT. Coronal and sagittal maximum intensity projections
are shown, obtained 9 days after KHT cell implant after IV administration of
B10MBq [
18F]FDG (A)o r[
18F]FLT (B).
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soverall tumour burden. The first investigated [
18F]FDG PET as a
means to resolve KHT lung metastases. The second incorporated
NLCQ-1 treatment. In total, seven animals that received saline and
three animals that received NLCQ-1 post-radiotherapy were
imaged. The KHT lung metastases were clearly evident in saline-
treated mice imaged 20 days post-radiotherapy, before the onset of
detrimental side effects (Figure 5A), although metastases were not
visible at day 13. In addition, there was evidence of lymph node
metastases that had not been recognised earlier (Figure 5A, arrow).
As observed in the efficacy studies, NLCQ-1 treatment was
associated with a reduced metastatic burden compared with saline
controls (Figure 5). The presence and absence of metastases in the
mice shown in Figures 5A and B was confirmed by (H&E) analysis
of lungs excised post-imaging (Figure 5C). The number of
metastases resolved by [
18F]FDG PET showed a highly significant
correlation (Po0.001) with those determined using the semi-
quantitative visual scoring method (Figure 5D).
To assess how well visible scoring and imaging correlated with
the presence of viable KHT clonogens within the lung tissue, lungs
were excised from three saline and three NLCQ-1-treated animals
21 days post-radiotherapy, disaggregated and plated for clonogenic
survival assays. Grade 0 lungs showed B1 clonogen per mg of lung
tissue, whereas lungs with visible signs of metastasis (grades 1–5)
showed an average of 165±57 clonogens per mg. Tumour tracer
uptake was normalised to that observed in the brain. There was no
significant difference in NUVs between treated and untreated
primary tumours or metastases. The NUVmax and NUV mean
were 1.1±0.3 and 1.0±0.3 for untreated primary tumours and
1.0±0.4 and 0.9±0.2 for treated tumours. Comparative values for
metastases were NUVmax 0.9±0.2 for both groups and NUVmean
1.4±0.2 and 1.3±0.3 for untreated and treated, respectively.
DISCUSSION
NLCQ-1 (NSC 709257) is the lead bioreductive agent from a
rational approach to develop nitroaromatics with weak DNA-
intercalating properties that may improve drug biodistribution
(Papadopoulou and Bloomer, 2003). Earlier studies have estab-
lished that NLCQ-1 has a good hypoxia-selectivity ratio and
combines well with radiotherapy and a range of chemotherapy
approaches in vivo (Papadopoulou et al, 2001a,b, 2002, 2005, 2006,
2007). Here, we show that NLCQ-1 is an excellent and well-
tolerated adjuvant to radiotherapy in the control of metastatic
tumour growth.
The KHT tumour model is a highly aggressive, locally invasive
sarcoma that spontaneously metastasises to the lungs. It is almost
unique in the reproducibility of the temporal onset of lung
metastases, making it an ideal system in which to study anti-
metastatic approaches. Our hypothesis in this study was that early
stage metastases have a reliance on hypoxia to initiate gene
expression changes that precipitate their subsequent growth. In
preliminary studies, we were able to show that early stage
microscopic KHT lung foci can be hypoxic. Up to day 5 post-
radiotherapy of the primary tumour, there was no evidence of
vascularisation of the hypoxic micrometastases. On the basis of the
presence of a target population in the metastases, bioreductive
treatment was given over 4 days starting 3 days after radiotherapy
of the primary tumour.
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Figure 5 KHT lung metastases can be resolved using [
18F]FDG PET.
Coronal and sagittal maximum intensity projections are shown, obtained
20 days after primary tumour radiotherapy and subsequent treatment with
saline (A) or NLCQ-1 (B) after IV administration of B10MBq [
18F]FDG.
Note multiple lung metastases in (A) and the presence of a lymph node
metastasis (arrow). H&E assessment of the lungs of the mice shown in
(A) and (B) confirms the presence of lung metastases in the saline-treated
mouse (C). The number of metastases resolved by PET shows an excellent
correlation with the semi-quantitative scoring of burden in excised lungs
(D). Closed symbols, control tumours; open symbols, NLCQ-1-treated
tumours.
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primary tumour, whereas NLCQ-1 had little effect. However,
NLCQ-1 was the most effective at controlling metastases. Improved
local control could conceivably influence the dissemination of
tumour cells from the primary site. However, the fact that NLCQ-1
has little impact on local control suggests an alternative mechanism
of action. We would argue that a direct effect against the hypoxic
metastases is a strong candidate. In an attempt to remove the
potential influence of primary tumour effects, the efficacy of NLCQ-
1 and tirapazamine against KHT lung metastases established after
tail-vein injection was assessed. Neither agent significantly affected
metastatic growth. The apparent differences in efficacy against
spontaneous vs experimental metastases perhaps supports that
NLCQ-1 is indeed targeting an early step in spontaneous
metastasis. Further, it may suggest that there are pathophysiologic
differences between the two models. This may be associated with
potential route of dissemination, given that cells could distribute
from a primary tumour through lymphatic or blood vessels,
whereas tail-vein injection forces dissemination through the latter
route. Interestingly, pathological assessment of lungs from the
spontaneous groups suggested lymphatic dissemination (data not
shown). This speculation is perhaps supported by the presence of
lymph node involvement as identified by [
18F]FDG PET.
In our earlier studies, tirapazamine given before radiotherapy
was able to reduce subsequent metastases formation, whereas
RB6145 showed little effect (Lunt et al, 2005). Similarly, NLCQ-1
was unable to reduce metastatic dissemination when given pre-
radiotherapy (data not shown). We hypothesised that the hypoxic
primary tumour cells that lay at intermediate oxygen concentra-
tions may be the most important target population in this context
as these would be removed by tirapazamine, but not RB6145 or
NLCQ-1 that require more stringent hypoxia for bioactivation
(Koch, 1993; K Williams and MV Papadopoulou, unpublished
data). Further tirapazamine was subsequently shown to have
anti-angiogenic properties (Huxham et al, 2006), which may have
impacted on the differential response. In this study, tirapazamine
performed less well than the nitroimidazoles when given after
radiotherapy. One possible explanation is that the bioavailability of
tirapazamine is poorer in the lung tumours, perhaps being
compromised by metabolism in relatively ‘oxygenated’ regions
and by the fact that the foci seem effectively avascular (Kyle and
Minchinton, 1999; Hicks et al, 2006). As NLCQ-1 was specifically
designed to have enhanced penetration compared with other
non-nitroimidazole-based bioreductives (Papadopoulou and Bloo-
mer, 2003), this perhaps explains its enhanced activity in the
current studies and highlights that when hypoxia-selective
cytotoxins are used in conjunction with conventional therapy,
oxygen dependence of activity, bioavailability and precise mechan-
ism of cytotoxicity should all be taken into account to achieve an
optimal response.
Although the KHT is an optimal model in many respects, one
issue is that it is not possible to readily establish genetically
modified clonal populations from these cells. This negates the
possibility of using such approaches as bio-luminescence as
non-invasive approaches to monitor disseminated tumour growth.
We investigated whether the lung metastases could be resolved
using [
18F]FDG PET. The KHT model both established subcuta-
neously and when disseminated to the lung showed excellent
uptake of [
18F]FDG. In addition, there was a highly significant
correlation between the metastatic profile obtained through
[
18F]FDG PET and that after histological examination of the lungs
after killing of the tumour-bearing mice. Importantly, lungs that
scored zero also had a low percentage of viable cells as measured
by clonogenic assay. In addition, they had either no or single
metastases discernible by [
18F]FDG PET. This indicates that there
is not significant viable cell mass escaping detection with [
18F]FDG
PET. As was observed in the efficacy studies, NLCQ-1 seemed to
reduce the metastases detected by [
18F]FDG PET at 20 days post-
radiotherapy. Although partial volume effects will lead to a
lessening of metastatic SUVs (Soret et al, 2007), as the tumour
sizes (where present) were comparable between groups, the effect
will occur to a similar extent irrespective of treatment. Although
SUVs were reduced in treated metastases, this difference
disappeared when uptake was normalised to the brain. As brain
uptake should be similar between conditions, this suggests that
drug treatment may have some systemic effect on tracer uptake,
although greater study numbers (including data on blood pool
activity) would be needed to confirm this. Recently, published
observations confirm the uptake of [
18F]FDG in primary KHT
tumours (Liu et al, 2009), and show good uptake of [
18F]fluoro-
acetate and [
18F]fluoromisonidazole in this model. Given that our
data also show strong uptake of [
18F]FLT in primary tumours, this
suggests that this fast-growing KHT model has particular usage in
longitudinal PET-based imaging studies to assess tumour response
to a range of targeted therapies in an immunocompetent host.
Overall, we summarise that bioreductive agents such as NLCQ-1
could have potential usage as adjuvants to radiotherapy in the
control of metastatic disease and that clinically applicable non-
invasive PET imaging can be used to monitor drug efficacy in the
KHT model. Earlier studies have shown that bioreductive
strategies synergise not only with radiotherapy, but also commonly
used chemo- and chemo-radiotherapy in which hypoxia limits the
effectiveness of treatment (Papadopoulou et al, 2001a, 2002, 2006;
Le et al, 2009). The addition of hypoxia-selective chemotherapy
alongside conventionally used clinical cancer therapy offers an
attractive approach to target secondary disease, which remains the
main cause of death in cancer patients.
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